Management of immunosuppression in the treatment of chronic lymphocytic leukemia

[1]  R. Greil,et al.  Mimicking the microenvironment in chronic lymphocytic leukaemia – where does the journey go? , 2013, British Journal of Haematology.

[2]  C. Croce,et al.  The Nature of the Antigen Determines Leukemia Development and Behavior in the Eμ-TCL1 Transgenic Mouse Model of CLL , 2012 .

[3]  V. Vullo,et al.  Current trends in management of hepatitis B virus reactivation in the biologic therapy era. , 2011, World journal of gastroenterology.

[4]  Celine M Vachon,et al.  Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. , 2011, Blood.

[5]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[6]  V. Morrison.  Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. , 2010, Best practice & research. Clinical haematology.

[7]  L. Pleyer,et al.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches , 2009, Nature Reviews Clinical Oncology.

[8]  J. Gribben,et al.  Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab , 2009, Annals of Hematology.

[9]  Thomas F. Smith,et al.  Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Grever,et al.  Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Keating,et al.  Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.

[12]  R. Greil,et al.  Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. , 2006, Cancer treatment reviews.

[13]  H. Einsele,et al.  Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[15]  P. Chiusolo,et al.  Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. , 2004, Haematologica.

[16]  R. Rosenquist,et al.  Similar Humoral Immunity Parameters in Chronic Lymphocytic Leukemia Patients Independent of VH Gene Mutation Status , 2004, Leukemia and Lymphoma.

[17]  M. Sinisalo,et al.  Vaccination Against Infections in Chronic Lymphocytic Leukemia , 2003, Leukemia & lymphoma.

[18]  A. Hartkamp,et al.  Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. , 2001, Vaccine.

[19]  M. Grever,et al.  Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. , 2000, Blood.

[20]  S. Molica,et al.  Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. , 1996, Haematologica.

[21]  A. Randomized.  Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .